![Ibrahim Dagher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ibrahim Dagher
Keine laufenden Positionen mehr
Vermögen: 79 515 $ am 30.06.2026
Profil
Ibrahim B. Dagher worked as Senior Medical Director at Labcorp Drug Development, Inc. from 2018 to 2019.
From 2019 to 2021, served as Chief Medical Officer-WCG MedAvante-ProPhase at Cadent Therapeutics, Inc. Held the position of Chief Medical Officer at MedAvante-ProPhase, Inc. Worked as Chief Medical Officer at Enveric Biosciences, Inc. from 2021 to 2023.
From 2024 to 2026, held the role of Chief Medical Officer & Executive Vice President at Brainstorm Cell Therapeutics, Inc. Completed undergraduate education at Université de Bordeaux and Faculté De Médecine Necker Enfants Malades Université.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.02.2026 | 79’515 ( 0.72% ) | 79 515 $ | 30.06.2026 |
Ehemalige bekannte Positionen von Ibrahim Dagher
| Unternehmen | Position | Ende |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 26.07.2026 |
| ENVERIC BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2023 |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Corporate Officer/Principal | 01.12.2021 |
| COVANCE INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
MedAvante-ProPhase, Inc.
 MedAvante-ProPhase, Inc. Information Technology ServicesTechnology Services Provides echnology-enabled signal detection solutions in clinical trials of treatments for nervous system disorders | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Ibrahim Dagher
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
30
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Labcorp Drug Development, Inc.
 Labcorp Drug Development, Inc. Medical/Nursing ServicesHealth Services Provides medical laboratory testing and drug development services | Health Services |
Brainstorm Cell Therapeutics, Inc.
 Brainstorm Cell Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company, which develops innovative adult stem cell therapeutic products | Health Technology |
Université de Bordeaux
 Université de Bordeaux Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Health Technology |
MedAvante-ProPhase, Inc.
MedAvante-ProPhase, Inc. Information Technology ServicesTechnology Services Provides echnology-enabled signal detection solutions in clinical trials of treatments for nervous system disorders | Technology Services |
Faculté De Médecine Necker Enfants Malades Université
 Faculté De Médecine Necker Enfants Malades Université Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enveric Biosciences, Inc.
 Enveric Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Develops cannabinoid medicines and combination therapies | Health Technology |
